Ayahuasca has aroused increasing interest due to its therapeutic effects. However, its effects on cognition are poorly understood. Hence, a systematic review evaluating the cognitive effects of ayahuasca was conducted.
Method:
This systematic review was conducted in accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A comprehensive search was performed in PubMed, Web of Science, PsycINFO, SciELO, and LILACS using terms related to ayahuasca, neuropsychology, and social cognition, encompassing all studies published up to March 25, 2025. Human observational, experimental, and clinical studies assessing neuropsychological performance or social cognition following ayahuasca administration were included. Titles, abstracts, and full texts were independently screened by two reviewers, with disagreements resolved with a third reviewer.
Results:
A total of 16 articles were selected, including observational (n = 11) and experimental (n = 5) studies. The results indicated distinct effects of ayahuasca on cognition. In the short term, improvements in functions such as working memory and cognitive flexibility were observed and attributed to neurochemical modulation of cortical networks. Regarding social cognition, observational studies have reported an increase in empathy and emotion recognition, while experimental studies have only observed reduction in reaction times. Long-term studies in general did not observe neuropsychological deficits, with some studies reporting improved memory and executive function.
Conclusions:
Although these findings are promising, there are methodological limitations, such as small sample sizes, diverse administration protocols, the observational nature of several studies, and possible learning effects. Further controlled, randomized studies are needed to elucidate the underlying mechanisms and consolidate the evidence. The PROSPERO ID for this study is CRD42024559125.
AdolphsR (2009) The social brain: Neural basis of social knowledge. Annual Review of Psychology60: 693–716.
2.
ArioliMCrespiCCanessaN (2018) Social cognition through the lens of cognitive and clinical neuroscience. BioMed Research International2018(1): 4283427.
3.
BaddeleyA (2012) Working memory: Theories, models, and controversies. Annual Review of Psychology63: 1–29.
4.
BălăeţM (2022) Psychedelic cognition—The unreached Frontier of psychedelic science. Frontiers in Neuroscience16: 832375.
5.
BarbosaPCRStrassmanRJDa SilveiraDX, et al. (2016) Psychological and neuropsychological assessment of regular hoasca users. Comprehensive Psychiatry71: 95–105.
6.
BarrettFSCarbonaroTMHurwitzE, et al. (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Effects on cognition. Psychopharmacology235(10): 2915–2927.
7.
BasedowLAMajićTHafizNJ, et al. (2024) Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA—A systematic review and meta-analysis. Scientific Reports14(1): 14782.
8.
BeaudoinCBeauchampM (2020) Social cognition. In: Handbook of Clinical Neurology, vol. 173. Elsevier, pp.255–264.
9.
BoraEBerkM (2016) Theory of mind in major depressive disorder: A meta-analysis. Journal of Affective Disorders191: 49–55.
10.
BousoJCFábregasJMAntonijoanRM, et al. (2013) Acute effects of ayahuasca on neuropsychological performance: Differences in executive function between experienced and occasional users. Psychopharmacology230(3): 415–424.
11.
BousoJCGonzálezDFondevilaS, et al. (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study. Plos One7(8): e42421.
12.
BousoJCPalhano-FontesFRodríguez-FornellsA, et al. (2015) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. European Neuropsychopharmacology25(4): 483–492.
13.
ButtonKSIoannidisJPAMokryszC, et al. (2013) Power failure: Why small sample size undermines the reliability of neuroscience. Nature Reviews. Neuroscience14(5): 365–376.
14.
CallawayJC (2005) Various alkaloid profiles in decoctions of Banisteriopsis caapi. Journal of Psychoactive Drugs37(2): 151–155.
15.
CallawayJCGrobCS (1998) Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. Journal of Psychoactive Drugs30(4): 367–369.
16.
CapelaJPFernandesERemiãoF, et al. (2007) Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons. NeuroToxicology28(4): 868–875.
17.
CardosoCGVianaMDB (2023) Psychedelics and cognitive function: A systematic review. Research, Society and Development12(14): e16121444436.
18.
Carhart-HarrisRLErritzoeDWilliamsT, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences109(6): 2138–2143.
19.
Carhart-HarrisRLGoodwinGM (2017) The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology42(11): 2105–2113.
20.
CarterOLBurrDCPettigrewJD, et al. (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. Journal of Cognitive Neuroscience17(10): 1497–1508.
21.
CavannaFMullerSde la FuenteLA, et al. (2022) Microdosing with psilocybin mushrooms: A double-blind placebo-controlled study. Translational Psychiatry12(1): 307.
22.
ChaiWJAbd HamidAIAbdullahJM (2018) Working memory from the psychological and neurosciences perspectives: A review. Frontiers in Psychology9: 00401.
23.
ColomRKaramaSJungRE, et al. (2010) Human intelligence and brain networks. Dialogues in Clinical Neuroscience12(4): 489–501.
24.
CostaSPMCarvalhoKCGomesIN, et al. (2024) Potential therapeutic use of ayahuasca: A literature review. Acta Amazonica54: e54cp23182.
25.
CrossenJRWiensAN (1994) Comparison of the Auditory-Verbal Learning Test (AVLT) and California Verbal Learning Test (CVLT) in a sample of normal subjects. Journal of Clinical and Experimental Neuropsychology16(2): 190–194.
26.
da SilveiraDXGrobCSde RiosMD, et al. (2005) Ayahuasca in adolescence: A preliminary psychiatric assessment. Journal of Psychoactive Drugs37(2): 129–133.
27.
DakicVMacielRDMDrummondHK, et al. (2016) Harmine stimulates proliferation of human neural progenitors. PeerJ4: e2727.
28.
DaumannJHeekerenKNeukirchA, et al. (2008) Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology200(4): 573–583.
29.
de Castro-NetoEFda CunhaRHda SilveiraDX, et al. (2013) Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World Journal of Biological Chemistry4(4): 141–147.
30.
DeliganisAVPiercePAPeroutkaSJ (1991) Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. Biochemical Pharmacology41(11): 1739–1744.
31.
DolderPCSchmidYMüllerF, et al. (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology41(11): 2638–2646.
32.
dos SantosRGBousoJCHallakJEC (2017) Ayahuasca: What mental health professionals need to know. Archives of Clinical Psychiatry (São Paulo)44: 103–109.
33.
dos SantosRGHallakJEC (2017) Effects of the natural β-carboline alkaloid harmine, a main constituent of ayahuasca, in memory and in the hippocampus: A systematic literature review of preclinical studies. Journal of Psychoactive Drugs49(1): 1–10.
34.
dos SantosRGOsórioFDLCrippaJAS, et al. (2016) Antidepressive and anxiolytic effects of ayahuasca: A systematic literature review of animal and human studies. Brazilian Journal of Psychiatry38: 65–72.
35.
dos SantosRGOsórioFDLRochaJM, et al. (2021) Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: A pilot, proof-of-concept, randomized, placebo-controlled trial. Journal of Clinical Psychopharmacology41(5): 540–550.
36.
DossMKKloftLMasonNL, et al. (2025) Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study. Journal of Psychopharmacology39(4): 339–349.
37.
DossMKPovažanMRosenbergMD, et al. (2021) Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry11(1): 574.
38.
EggerKGudmundsenFJessenNS, et al. (2023) A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine. Frontiers in Pharmacology14: 1140656.
39.
Falchi-CarvalhoMPalhano-FontesFWießnerI, et al. (2025) Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: A phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology50(6): 895–903.
40.
FonsecaAMDos SantosRGDe MedeirosLS, et al. (2025) Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: A cross-sectional study with ritual users. European Archives of Psychiatry and Clinical Neuroscience275(2): 519–531.
41.
FontanillaDJohannessenMHajipourAR, et al. (2009) The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science (New York, N.Y.)323(5916): 934–937.
42.
GoelVGrafmanJ (2000) Role of the right prefrontal cortex in ill-structured planning. Cognitive Neuropsychology17(5): 415–436.
43.
GonçalvesJLuísÂGallardoE, et al. (2023) A systematic review on the therapeutic effects of ayahuasca. Plants12(13): 2573.
44.
GoodwinGMAaronsonSTAlvarezO, et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine387(18): 1637–1648.
45.
GoodwinGMAaronsonSTAlvarezO, et al. (2025) The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. Journal of Affective Disorders372: 523–532.
46.
GoodwinGMCroalMFeifelD, et al. (2023) Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology48(10): 1492–1499.
47.
Gouzoulis-MayfrankEHeekerenKNeukirchA, et al. (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry38: 301–311.
48.
Gouzoulis-MayfrankESchreckenbergerMSabriO, et al. (1999) Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG. Neuropsychopharmacology20(6): 565–581.
49.
GrobCSMckennaDJCallawayJC, et al. (1996) Human psychopharmacology of Hoasca, a plant hallucinogen used in ritual context in Brazil:The Journal of Nervous and Mental Disease184(2): 86–94.
50.
HowickJFriedemannCTsakokM, et al. (2013) Are treatments more effective than placebos? A systematic review and meta-analysis. PloS One8(5): e62599.
51.
HuttenNRPWMasonNLDolderPC, et al. (2020) Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. European Neuropsychopharmacology41: 81–91.
52.
IoannidisJPA (2005) Why most published research findings are false. PLoS Medicine2(8): e124.
53.
IoannidisJPA (2016) The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. The Milbank Quarterly94(3): 485–514.
54.
JungREHaierRJ (2007) The Parieto-Frontal Integration Theory (P-FIT) of intelligence: Converging neuroimaging evidence. The Behavioral and Brain Sciences30(2): 135–154; discussion 154–187.
55.
JungwirthJvon RotzRDziobekI, et al. (2025) Psilocybin increases emotional empathy in patients with major depression. Molecular Psychiatry30(6): 2665–2672.
56.
KaasikHSouzaRCZZandonadiFS, et al. (2021) Chemical composition of traditional and analog ayahuasca. Journal of Psychoactive Drugs53(1): 65–75.
57.
KeiserMJSetolaVIrwinJJ, et al. (2009) Predicting new molecular targets for known drugs. Nature462(7270): 175–181.
58.
KiragaMKMasonNLUthaugMV, et al. (2021) Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being. Frontiers in Pharmacology12: 721537.
59.
KometerMSchmidtABachmannR, et al. (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry72(11): 898–906.
60.
KometerMSchmidtAJänckeL, et al. (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience33(25): 10544–10551.
61.
KrauseFCLinardatosEFrescoDM, et al. (2021) Facial emotion recognition in major depressive disorder: A meta-analytic review. Journal of Affective Disorders293: 320–328.
62.
KuypersKPNgLErritzoeD, et al. (2019) Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology (Oxford, England)33(9): 1039–1057.
63.
KuypersKPRibaJde la Fuente RevengaM, et al. (2016) Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology233(18): 3395–3403.
64.
LiL-JMoYShiZ-M, et al. (2024) Psilocybin for major depressive disorder: A systematic review of randomized controlled studies. Frontiers in Psychiatry15: 1416420.
65.
LoftusEF (2005) Planting misinformation in the human mind: A 30-year investigation of the malleability of memory. Learning & Memory12(4): 361–366.
66.
LyCGrebACCameronLP, et al. (2018) Psychedelics promote structural and functional neural plasticity. Cell Reports23(11): 3170–3182.
67.
MagaraggiaIKuiperesZSchreiberR (2021) Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. Neurobiology of Learning and Memory183: 107467.
68.
McKennaDJ (2004) Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacology & Therapeutics102(2): 111–129.
69.
McKennaDJTowersGHNAbbottF (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents ofAyahuasca. Journal of Ethnopharmacology10(2): 195–223.
70.
MoherDShamseerLClarkeM, et al. (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews4(1): 1.
71.
Morales-GarciaJACalleja-CondeJLopez-MorenoJA, et al. (2020) N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Translational Psychiatry10(1): 331.
72.
MoritzSWoodwardTSRodriguez-RaeckeR (2006) Patients with schizophrenia do not produce more false memories than controls but are more confident in them. Psychological Medicine36(5): 659–667.
73.
Morales-GarcíaJAde la Fuente RevengaMAlonso-GilS, et al. (2017) The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Scientific Reports7(1): 5309.
74.
MüllerFZaczekHBeckerAM, et al. (2025) Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med6(9): 100725.
75.
MurphyRJMuthukumaraswamySde WitH (2024) Microdosing psychedelics: Current evidence from controlled studies. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging9(5): 500–511.
76.
Murphy-BeinerASoarK (2020) Ayahuasca’s ‘afterglow’: Improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology237(4): 1161–1169.
NormanMAEvansJDMillerWS, et al. (2000) Demographically corrected norms for the California Verbal Learning Test. Journal of Clinical and Experimental Neuropsychology22(1): 80–94.
80.
Palhano-FontesFAndradeKCTofoliLF, et al. (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PloS One10(2): e0118143.
81.
Palhano-FontesFBarretoDOniasH, et al. (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine49(4): 655–663.
82.
PasquiniLPalhano-FontesFAraujoDB (2020) Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. Journal of Psychopharmacology (Oxford, England)34(6): 623–635.
83.
Pérez-MataNDigesM (2024) False memories in forensic psychology: Do cognition and brain activity tell the same story?Frontiers in Psychology15: 1327196.
84.
PokornyTPrellerKHKometerM, et al. (2017) Effect of psilocybin on empathy and moral decision-making. The International Journal of Neuropsychopharmacology20(9): 747–757.
85.
PosnerMIPetersenSE (1990) The attention system of the human brain. Annual Review of Neuroscience13: 25–42.
86.
ProchazkovaLLippeltDPColzatoLS, et al. (2018) Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Psychopharmacology235(12): 3401–3413.
87.
QuednowBBKometerMGeyerMA, et al. (2012) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology37(3): 630–640.
88.
RaghavendraPAHegdeSPhilipM, et al. (2025) Socio-cognitive processes in mild-moderate depression. Frontiers in Psychology16: 1541725.
89.
RamaekersJGMallaroniPKloftL, et al. (2023) Altered state of consciousness and mental imagery as a function of N, N -dimethyltryptamine concentration in ritualistic ayahuasca users. Journal of Cognitive Neuroscience35(9): 1382–1393.
90.
RivellaCViterboriPUsaiMC (2025) Sustained attention and inhibitory control: Age and sex related difference in children and adolescents using a CPT with distracting events. Frontiers in Psychology16: 1609537.
91.
RochaJMRossiGNDe Lima OsórioF, et al. (2021) Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers: A pilot, proof-of-concept, randomized controlled trial. Journal of Clinical Psychopharmacology41(3): 267–274.
92.
RossiGNDiasICDSBakerG, et al. (2022) Ayahuasca, a potentially rapid acting antidepressant: Focus on safety and tolerability. Expert Opinion on Drug Safety21(6): 789–801.
93.
RossiGNRochaJMOsórioFL, et al. (2023) Interactive effects of ayahuasca and cannabidiol in social cognition in healthy volunteers: A pilot, proof-of-concept, feasibility, randomized-controlled trial. Journal of Clinical Psychopharmacology43(4): 339–349.
94.
SanchesRFde Lima OsórioFDos SantosRG, et al. (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology36(1): 77–81.
95.
SanchezTARamosLRAraujoF, et al. (2024) Emotion regulation effects of Ayahuasca in experienced subjects during implicit aversive stimulation: An fMRI study. Journal of Ethnopharmacology320: 117430.
96.
SantosMCNavickieneSGaujacA (2017) Determination of tryptamines and β-carbolines in ayahuasca beverage consumed during Brazilian religious ceremonies. Journal of AOAC International100(3): 820–824.
97.
SennaSSchwabBMeloHM, et al. (2022) Social cognition and suicide-related behaviors in depression: A cross-sectional, exploratory study. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil: 1999)44(6): 639–643.
98.
SmithMLMilnerB (1981) The role of the right hippocampus in the recall of spatial location. Neuropsychologia19(6): 781–793.
99.
SolajaIHaldaneKMasonN, et al. (2024) Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality. Neuroscience and Biobehavioral Reviews158: 105570.
100.
SquireLRZola-MorganS (1991) The medial temporal lobe memory system. Science (New York, N.Y.)253(5026): 1380–1386.
101.
StrassmanRJQuallsCR (1994) Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Archives of General Psychiatry51(2): 85–97.
102.
StroudJBFreemanTPLeechR, et al. (2018) Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology235(2): 459–466.
103.
StussDTAlexanderMP (2000) Executive functions and the frontal lobes: A conceptual view. Psychological Research63(3–4): 289–298.
104.
SuayDAicherHDKometerM, et al. (2025) Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces. NeuroImage313: 121247.
105.
SumiyoshiT (2015) Verbal memory. Handbook of Experimental Pharmacology228: 237–247.
106.
SzaboAKovacsAFrecskaE, et al. (2014) Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PloS One9(8): e106533.
107.
Torrado PachecoAOlsonRJGarzaG, et al. (2023) Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology48(7): 1011–1020.
108.
Velit-SalazarMRShiromaPRCherianE (2024) A systematic review of the neurocognitive effects of psychedelics in healthy populations: Implications for depressive disorders and post-traumatic stress disorder. Brain Sciences14(3): 248.
109.
VollenweiderFXPrellerKH (2020) Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews. Neuroscience21(11): 611–624.
110.
VollenweiderFXCsomorPAKnappeB, et al. (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology32(9): 1876–1887.
111.
WittmannMCarterOHaslerF, et al. (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology (Oxford, England)21(1): 50–64.
112.
ZappulloIConsonMJansenP, et al. (2025) Editorial: Visuospatial and visuoconstructional abilities and disorders across the life span. Frontiers in Psychiatry16: 1604144.
113.
ZucchellaCFedericoAMartiniA, et al. (2018) Neuropsychological testing. Practical Neurology18(3): 227–237.
